Efficacy signals, long-term exposure and safety data from a phase 1-2 study of a cell-penetrating peptide antagonist of CEBP beta, a novel target, in patients (pts) with refractory solid tumors

E. Fontana,A. Williams, G. Falchook,N. Lakhani,T. R. J. Evans, V. Gondi, F. Iwamoto, M. McKean, S. Symeonides, N. Butowski, A. McLaren, J. Henry, R. Buerki, J. Rotolo, G. Capiaux, R. Michel, S. Kaesshaefer, E. Wiegert, A. Bexon

European Journal of Cancer（2022）

引用 0|浏览2